Peripheral Chemoreceptor Hypersensitivity

• Piotr Ponikowski

  From Clinical Cardiology, NHLI, London, UK (P.P., T.P.C., S.D.A., D.P.F., W.D., P.A.P.-W., M.F.P., A.J.S.C.); the Cardiology Department, Clinical Military Hospital, Wroclaw, Poland (P.P., W.B.); and the Franz-Volhard-Klinik (Charité, Campus Berlin-Buch) at Max-Delbrück-Centrum, Berlin, Germany (S.D.A.).

• Tuan Peng Chua

  From Clinical Cardiology, NHLI, London, UK (P.P., T.P.C., S.D.A., D.P.F., W.D., P.A.P.-W., M.F.P., A.J.S.C.); the Cardiology Department, Clinical Military Hospital, Wroclaw, Poland (P.P., W.B.); and the Franz-Volhard-Klinik (Charité, Campus Berlin-Buch) at Max-Delbrück-Centrum, Berlin, Germany (S.D.A.).

• Stefan D. Anker

  From Clinical Cardiology, NHLI, London, UK (P.P., T.P.C., S.D.A., D.P.F., W.D., P.A.P.-W., M.F.P., A.J.S.C.); the Cardiology Department, Clinical Military Hospital, Wroclaw, Poland (P.P., W.B.); and the Franz-Volhard-Klinik (Charité, Campus Berlin-Buch) at Max-Delbrück-Centrum, Berlin, Germany (S.D.A.).

• Darrel P. Francis

  From Clinical Cardiology, NHLI, London, UK (P.P., T.P.C., S.D.A., D.P.F., W.D., P.A.P.-W., M.F.P., A.J.S.C.); the Cardiology Department, Clinical Military Hospital, Wroclaw, Poland (P.P., W.B.); and the Franz-Volhard-Klinik (Charité, Campus Berlin-Buch) at Max-Delbrück-Centrum, Berlin, Germany (S.D.A.).

• Wolfram Doehner

  From Clinical Cardiology, NHLI, London, UK (P.P., T.P.C., S.D.A., D.P.F., W.D., P.A.P.-W., M.F.P., A.J.S.C.); the Cardiology Department, Clinical Military Hospital, Wroclaw, Poland (P.P., W.B.); and the Franz-Volhard-Klinik (Charité, Campus Berlin-Buch) at Max-Delbrück-Centrum, Berlin, Germany (S.D.A.).

• Waldemar Banasiak

  From Clinical Cardiology, NHLI, London, UK (P.P., T.P.C., S.D.A., D.P.F., W.D., P.A.P.-W., M.F.P., A.J.S.C.); the Cardiology Department, Clinical Military Hospital, Wroclaw, Poland (P.P., W.B.); and the Franz-Volhard-Klinik (Charité, Campus Berlin-Buch) at Max-Delbrück-Centrum, Berlin, Germany (S.D.A.).

• Phillip A. Poole-Wilson

  From Clinical Cardiology, NHLI, London, UK (P.P., T.P.C., S.D.A., D.P.F., W.D., P.A.P.-W., M.F.P., A.J.S.C.); the Cardiology Department, Clinical Military Hospital, Wroclaw, Poland (P.P., W.B.); and the Franz-Volhard-Klinik (Charité, Campus Berlin-Buch) at Max-Delbrück-Centrum, Berlin, Germany (S.D.A.).

• Massimo F. Piepoli

  From Clinical Cardiology, NHLI, London, UK (P.P., T.P.C., S.D.A., D.P.F., W.D., P.A.P.-W., M.F.P., A.J.S.C.); the Cardiology Department, Clinical Military Hospital, Wroclaw, Poland (P.P., W.B.); and the Franz-Volhard-Klinik (Charité, Campus Berlin-Buch) at Max-Delbrück-Centrum, Berlin, Germany (S.D.A.).

• Andrew J.S. Coats

  From Clinical Cardiology, NHLI, London, UK (P.P., T.P.C., S.D.A., D.P.F., W.D., P.A.P.-W., M.F.P., A.J.S.C.); the Cardiology Department, Clinical Military Hospital, Wroclaw, Poland (P.P., W.B.); and the Franz-Volhard-Klinik (Charité, Campus Berlin-Buch) at Max-Delbrück-Centrum, Berlin, Germany (S.D.A.).

書誌事項

タイトル別名

• An Ominous Sign in Patients With Chronic Heart Failure

抄録

Background Peripheral chemoreceptor hypersensitivity is a feature of abnormal cardiorespiratory reflex control in chronic heart failure (CHF) and may contribute to sympathetic overactivity, attenuated baroreflex sensitivity (BRS), and excessive ventilation during exercise. We studied whether augmented peripheral chemosensitivity carries independent prognostic significance. Methods and Results We assessed peripheral chemosensitivity (ventilatory response to hypoxia using transient inhalation of pure nitrogen) and BRS (phenylephrine and spectral methods) in 80 consecutive CHF patients (age 58±9 years; left ventricular ejection fraction [LVEF] 24±12%; peak oxygen consumption [peak V̇ o 2 ] 18±7 mL −1 · min −1 ). CHF patients demonstrated augmented peripheral chemosensitivity and decreased BRS (all P <0.01 versus reference values). During follow-up (median 41 months, >3 years in all survivors), 37 patients died. High peripheral chemosensitivity (>0.72 L · min −1 · %Sa o 2 −1 ) predicted impaired survival (hazard ratio 3.2, 95% CI 1.6 to 6.0, P =0.0006). In the 27 patients (34%) with high peripheral chemosensitivity, 3-year survival was 41% (95% CI 22% to 60%) compared with 77% (66% to 89%) in 53 patients with normal chemosensitivity ( P =0.0002). In multivariate analyses, augmented chemosensitivity independently predicted death (hazard ratio 2.8, 95% CI 1.5 to 5.5, adjusted for age, peak V̇ o 2 , and V̇ e /V̇ co 2 [ P =0.002]; hazard ratio 2.6, 95% CI 1.3 to 5.1, adjusted for age, LVEF, and peak V̇ o 2 [ P =0.008]). Depressed BRS was related to unfavorable prognosis in univariate analysis ( P =0.05) but not in multivariate analyses. Conclusions Hypersensitivity of the peripheral chemoreceptors independently predicts adverse prognosis in ambulatory patients with CHF. This hyperactive excitatory reflex, through its inhibitory effect on the baroreflex, may be the reason for the previously observed prognostic association of the latter.

収録刊行物

• Circulation

  Circulation 104 (5), 544-549, 2001-07-31

  Ovid Technologies (Wolters Kluwer Health)

キーワード

• Physiology (medical)
• Cardiology and Cardiovascular Medicine

詳細情報

• CRID: 1362544419112513280
• NII論文ID: 30029738669
• DOI: 10.1161/hc3101.093699
• ISSN: 15244539
• ISSN: 00097322
• ISSN: http://id.crossref.org/issn/00097322
• Web Site: https://www.ahajournals.org/doi/full/10.1161/hc3101.093699
• データソース種別:
  • Crossref
  • CiNii Articles